Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

bioAffinity Technologies (BIAF) Revenue (2022 - 2026)

bioAffinity Technologies has reported Revenue over the past 5 years, most recently at $1.4 million for Q1 2026.

  • Quarterly Revenue fell 27.09% to $1.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $5.7 million through Mar 2026, down 35.75% year-over-year, with the annual reading at $6.2 million for FY2025, 34.18% down from the prior year.
  • Revenue was $1.4 million for Q1 2026 at bioAffinity Technologies, down from $1.6 million in the prior quarter.
  • Over five years, Revenue peaked at $2.4 million in Q1 2024 and troughed at $921.0 in Q1 2023.
  • The 5-year median for Revenue is $1.4 million (2025), against an average of $1.2 million.
  • Year-over-year, Revenue soared 261180.24% in 2024 and then plummeted 47.05% in 2025.
  • A 5-year view of Revenue shows it stood at $2346.0 in 2022, then surged by 94245.95% to $2.2 million in 2023, then decreased by 0.26% to $2.2 million in 2024, then decreased by 27.85% to $1.6 million in 2025, then decreased by 15.15% to $1.4 million in 2026.
  • Per Business Quant, the three most recent readings for BIAF's Revenue are $1.4 million (Q1 2026), $1.6 million (Q4 2025), and $1.4 million (Q3 2025).